Streetbeat News

Stock Prices

ADBE

CRM

DOCU

NVDA

QQQ

The article discusses the recent tech rally, highlighting the performance of the QQQ index and Nvidia (NVDA). It suggests looking at other tech stocks like Salesforce (CRM) and Adobe (ADBE), which have also seen significant gains and are approaching all-time highs. Salesforce received an analyst upgrade and may raise subscription prices in 2024. Adobe's growth is outpacing DocuSign (DOCU), and both CRM and ADBE have potential to test new highs according to their chart setups.

Portfolio Pulse from Thrash Capital

January 26, 2024 | 7:34 pm

ALK

UAL

The FAA has not approved Boeing's (NYSE:BA) planned expansion for the 737 Max aircraft due to quality issues, but has allowed the 737 Max 9 to return to service for United Airlines (NASDAQ:UAL) and Alaska Air Group (NYSE:ALK). Moody's maintained Boeing's Baa2 rating with a stable outlook, despite considering the news as 'one step forward, two steps back.' Alaska Air plans to resume flights with the 737 Max 9, and United Airlines is expected to follow. Boeing's stock is up 1% on Friday but down 21% YTD.

Portfolio Pulse from Chris Katje

January 26, 2024 | 7:34 pm

APPF

CRBP

EHTH

NVVE

PCSA

TKLF

The Nasdaq Composite fell over 50 points while the Dow and S&P 500 traded mixed. Colgate-Palmolive (CL) reported better-than-expected Q4 results with a 7% sales growth. AppFolio (APPF), Corbus Pharmaceuticals (CRBP), and eHealth (EHTH) saw their shares rise after positive financial results and study data. Conversely, Yoshitsu (TKLF), Nuvve Holding (NVVE), and Processa Pharmaceuticals (PCSA) experienced significant drops in share prices due to a direct offering, public offering, and pricing of a public offering, respectively.

Portfolio Pulse from Avi Kapoor

January 26, 2024 | 7:32 pm

DYN

Dyne Therapeutics is reportedly considering its options in response to takeover interest, leading to a trading halt on its shares due to a circuit breaker, as reported by Bloomberg.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:31 pm

ALB

Albemarle Inc. (NYSE:ALB) saw a 1.31% increase in its stock price to $120.00 in the current market session, despite a 16.84% decrease over the past month and a 55.82% drop over the past year. The company's P/E ratio is lower than the Chemicals industry average, suggesting it could be undervalued or expected to perform worse than its peers. Investors are advised to consider the P/E ratio alongside other financial metrics and qualitative analysis for a comprehensive investment decision.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 7:30 pm

TSN

Piper Sandler analyst Michael Lavery has maintained a Neutral rating on Tyson Foods (NYSE:TSN) and increased the price target from $44 to $48.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:29 pm

HUM

Cantor Fitzgerald analyst Sarah James has downgraded Humana (NYSE:HUM) from Overweight to Neutral and reduced the price target from $597 to $391.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:26 pm

FXI

SPY

US Treasury Secretary Yellen has indicated that the US economy may experience some spillovers from China's financial turmoil, particularly if it results in slower growth among key Asian trade partners. However, she believes that any potential spillovers to the US economy will not be 'very large'.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:19 pm

WDC

Barclays analyst Tom O'Malley has maintained an Overweight rating on Western Digital (NASDAQ:WDC) and increased the price target from $65 to $70.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 7:15 pm

CALT

VERA

Vera Therapeutics Inc (NASDAQ:VERA) stock surged nearly 50% after positive 72-week data from a Phase 2b trial of atacicept for IgA nephropathy (IgAN). Analysts responded with rating upgrades and increased price targets. Oppenheimer initiated coverage with an Outperform rating and a $26 target. Raymond James upgraded to Strong Buy and raised their target from $29 to $37. Wedbush maintained a Neutral rating but increased their target from $16 to $21. The stock's volume significantly exceeded the average. Calliditas Therapeutics AB (NASDAQ:CALT), which also develops IgAN treatments, had its drug Tarpeyo approved by the FDA in December.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 7:13 pm